ClinicalTrials.gg
CompletedNCT03359291Updated Jun 22, 2025

Clinical Study to Investigate the Effect of Macitentan on the Concentrations of Rosuvastatin in the Blood of Healthy Male Subjects

A Phase 1 interventional study of Rosuvastatin and Macitentan in Healthy Subjects, sponsored by Actelion. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-22.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The aim of this Phase 1 trial is to study a potential drug-drug interaction between macitentan and rosuvastatin, a model substrate of various transporter proteins (e.g. in the gut).

Read the detailed description

Rosuvastatin is a substrate of various transporter proteins including breast cancer resistance protein (BCRP) and organic anion-transporting polypeptides (OATP). It is unknown to which extent macitentan has an effect, if any, on BCRP transporters, especially intestinal BCRP. The primary purpose of this Phase 1 study is to investigate the effect of macitentan on the pharmacokinetics of rosuvastatin, a model BCRP substrate.

02

Conditions studied

  • Healthy Subjects

Keywords

  • macitentan
  • rosuvastatin
  • pharmacokinetics
03

In context

Lead sponsor

Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.

Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.

First submitted after Actelion became part of Johnson & Johnson.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Principal Inclusion Criteria:

  • Signed in the local language prior to any study-mandated procedure.
  • Healthy male subjects aged between 18 and 55 years (inclusive) at screening.
  • No findings on the physical examination at screening.
  • of 18.0 to 30.0 kg/m2 (inclusive) at screening.
  • Systolic blood pressure 100-140 mmHg, diastolic blood pressure 60-90 mmHg, and pulse rate 50-90 beats per minute (inclusive), measured on the dominant arm, after 5 min in the supine position at screening.
  • 12-lead (ECG) without clinically relevant abnormalities, measured after 5 min in the supine position at screening.
  • Hematology and clinical chemistry test results not deviating from the normal range to a clinically relevant extent at screening.
  • Negative results from urine drug screen and alcohol breath test at screening and Day -1.
  • Ability to communicate well with the investigator, in the local language, and to understand and comply with the requirements of the study.

Principal Exclusion Criteria:

  • Known allergic reactions or to macitentan, rosuvastatin, any drug of the same classes, or any of their .
  • Any for rosuvastatin treatment.
  • History or clinical evidence of myopathy.
  • Subjects of Asian race.
  • Known hypersensitivity or allergy to natural rubber latex.
  • Values of hepatic aminotransferase ( and aspartate aminotransferase) outside of the normal range at screening.
  • or hematocrit outside of the normal range at screening.
  • History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study treatment(s) (appendectomy and herniotomy allowed, cholecystectomy not allowed).
  • Previous history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal reactions.
  • Veins unsuitable for intravenous puncture on either arm (e.g., veins that are difficult to locate, access or puncture, veins with a tendency to rupture during or after puncture).
  • Previous exposure to macitentan.
  • Previous exposure to rosuvastatin.
  • Treatment with another drug within 3 months prior to screening or participation in more than 3 investigational drug studies within 1 year prior to screening.
  • History or clinical evidence of alcoholism or drug abuse within the 3-year period prior to screening.
  • Excessive caffeine consumption, defined as ≥ 800 mg per day at screening.
  • Nicotine intake (e.g., smoking, nicotine patch, nicotine chewing gum or electronic cigarettes) within 3 months prior to screening and inability to refrain from nicotine intake from screening until End-Of-Study (EOS).
  • Previous treatment with any prescribed medications (including vaccines) or over-the-counter (OTC) medications (including herbal medicines such as St John's Wort, homeopathic preparations, vitamins, and minerals) within 3 weeks prior to first study treatment administration.
  • Loss of 250 mL or more of blood within 3 months prior to screening.
  • Positive results from the hepatitis serology, except for vaccinated subjects or subjects with past but resolved hepatitis, at screening.
  • Positive results from the serology at screening.
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
  • Legal incapacity or limited legal capacity at screening.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Sequence AB

    Subjects participate in two study periods: During the first period (treatment A), they receive a single oral dose of rosuvastatin on Day 1. During the second period (treatment B), they receive a single oral loading dose of macitentan on Day 5 and oral doses of macitentan from Day 6 to Day 16 (i.e., 11 doses). Subjects receive a single oral dose of 10 mg rosuvastatin concomitantly with macitentan in the morning of Day 10.

    Drug: Rosuvastatin · Drug: Macitentan

Interventions

  • Single oral dose of 10 mg rosuvastatin (film-coated tablet) on Day 1 and Day 10

  • Single oral dose of 30 mg macitentan (film-coated tablet) on Day 5 and 10 mg macitentan administered orally from Day 6 to Day 16

    Also known as: ACT-064992

06

What researchers measure

Primary outcomes

  1. AUC(0-inf) of rosuvastatin following administration of rosuvastatin alone (treatment A) and in combination with macitentan (treatment B)

    AUC(0-inf) is the area under the plasma concentration-time curves of rosuvastatin, calculated from time zero to the extrapolated infinite time

    Time frame: From Day1 to Day17 (treatment A: from Day1-Day5 and treatment B: from Day10-Day17)

  2. Cmax of rosuvastatin following administration of rosuvastatin alone (treatment A) and in combination with macitentan (treatment B)

    Cmax is the maximum observed plasma concentration and is directly derived from the individual plasma concentration time curves of rosuvastatin

    Time frame: From Day1 to Day17 (treatment A: from Day1-Day5 and treatment B: from Day10-Day17)

Secondary outcomes

  1. tmax of rosuvastatin following administration of rosuvastatin alone (treatment A) and in combination with macitentan (treatment B)

    The time to reach maximum plasma concentration (tmax) of rosuvastatin

    Time frame: From Day1 to Day17 (treatment A: from Day1-Day5 and treatment B: from Day10-Day17)

  2. t½ of rosuvastatin following administration of rosuvastatin alone (treatment A) and in combination with macitentan (treatment B)

    t½ is the terminal half-life of rosuvastatin and corresponds to the period of time required for the concentration levels of rosuvastatin to be reduced by one-half

    Time frame: From Day1 to Day17 (treatment A: from Day1-Day5 and treatment B: from Day10-Day17)

  3. AUC(0-t) of rosuvastatin following administration of rosuvastatin alone (treatment A) and in combination with macitentan (treatment B)

    AUC(0-t) is the area under the plasma concentration-time curve from time zero to time t of the last measured concentration above the limit of quantification of rosuvastatin

    Time frame: From Day1 to Day17 (treatment A: from Day1-Day5 and treatment B: from Day10-Day17)

  4. Trough plasma concentrations of macitentan and its metabolite ACT-132577

    Trough concentrations of macitentan and ACT-132577 are measured before oral administration of macitentan

    Time frame: From Day5 to Day17

  5. Change from baseline in supine blood pressure

    Change from baseline to each time point of measurement during study period

    Time frame: From Day1 to end-of-study visit (Day 26-28)

  6. Change from baseline in pulse rate

    Change from baseline to each time point of measurement during study period

    Time frame: From Day1 to end-of-study visit (Day 26-28)

  7. Change from baseline in heart rate (HR)

    Change from baseline to each time point of measurement during study period

    Time frame: From Day1 to end-of-study visit (Day 26-28)

  8. Change from baseline in ECG variables

    Change from baseline to each time point of measurement during study period in ECG variables: PR, QRS, QT, RR, and QT corrected for Bazett's and Fridericia's formulae (QTcB and QTcF, respectively)

    Time frame: From Day1 to end-of-study visit (Day 26-28)

  9. Change from baseline to end-of-study (EOS) in body weight

    Change in body weight measured in kg during study period

    Time frame: From Day1 to end-of-study visit (Day 26-28)

  10. Change from baseline in clinical laboratory tests

    Change from baseline to each time point of measurement during study period for clinical laboratory tests (hematology, clinical chemistry, serology)

    Time frame: From Day1 to end-of-study visit (Day 26-28)

  11. Incidence rate of treatment-emergent treatment-emergent adverse events (AEs) and serious adverse events (SAEs)

    Incidence rates of treatment-emergent AEs including abnormalities in ECG variables during each treatment as well as AEs leading to the discontinuation of study treatment. A treatment-emergent AE is any AE temporally associated with the use of a study treatment, whether or not considered related to the study treatment.

    Time frame: From Day1 to follow-up period (Day46-48)

07

Study locations

1 site
  • CRS Clinical Research Services Mannheim
    Mannheim, 68167, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Dec 2017, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2017
First posted
Dec 2, 2017
StartActual
Nov 3, 2017
Primary completionActual
Dec 4, 2017
CompletionActual
Dec 4, 2017
Last update
Jun 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03359291
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Dec 2, 2017
Start date
Nov 3, 2017
Primary completion
Dec 4, 2017
Completion
Dec 4, 2017
Last update
Jun 22, 2025

Study contacts

Shirin Bruderer, PhD
study director · Actelion

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rosuvastatin · Macitentan

Start the discussion